Calithera Biosciences Inc. said a combination of its product candidate CB-839 and chemotherapy drug capecitabine delayed disease progression in patients with advanced solid tumors that did not respond to treatment.
In the phase 1/2 trial, the combination helped delay disease progression by an median period of 26 weeks among seven patients with treatment-resistant advanced colorectal cancer with the PIKC3A mutation and had worsened after receiving one prior treatment regime containing fluoropyrimidine, a class of anti-cancer drugs.
The phase 1 part of the study aims to determine the safety and recommended dosage of the combination, while the phase 2 part seeks to assess the combination's effect in patients with late line PIK3CA mutant colorectal cancer.
Calithera is currently examining CB-839 in combination with standard of care treatments in phase 2 clinical trials involving multiple tumor types.
The 2018 American Society of Clinical Oncology meeting is expected to bring together more than 32,000 professionals from all over the world, with more than 2,500 study abstracts to be presented on-site and an additional 3,350 abstracts to be published online.
